ABL Bio Corp.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis, Matchpoint Will Seek Out Oral

The second quarter was a mixed bag of encouraging and disappointing news for the South Korean biopharma sector, ranging from cancellation of out-licensing deals and discontinuation of clinical trials

The last few years have been bittersweet for ABL Bio. After reaching a major deal with Sanofi in 2021, the South Korean biotech was excited because it was also discussing a potential tie-up with GSK

In the top alliance by deal value, ABL Bio entered a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio’s blood-brain barrier shu